Bioasis Technologies Inc (BTI):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Bioasis Technologies Inc (BTI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8028
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Bioasis Technologies Inc (BTI) is a developer and commercialize of pharmaceutical products and diagnostic technologies for central nervous system diseases and disorders. The company’s transcend program describes the proprietary carrier, p97 to deliver therapeutics and imaging agents across the blood brain barrier. It commercializes its business operations through Cognitest and Transcend names. BTI operates through research institutions and other biotechnology and pharmaceutical companies. The company provides services by conducting research and development with pharmaceutical companies and institutions to advance its technologies. BTI is headquartered in Richmond, British Columbia, Canada.

Bioasis Technologies Inc (BTI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Bioasis Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Bioasis Technologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Bioasis Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Bioasis Technologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Bioasis Technologies Inc, Medical Devices Deals, 2012 to YTD 2018 10
Bioasis Technologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Bioasis Technologies Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Bioasis Technologies and BioAgilytix Enter into Co-Development Agreement 12
Bioasis Technologies Enters into Agreement with Wuxi Biologics 13
biOasis Technologies Enters into Research Agreement with Brigham and Women’s Hospital 14
Bioasis Enters into Collaborative Research Agreement with Brain Canada 15
biOasis Technologies Enters Into Research Agreement With UCB 16
biOasis Technologies Enters Into Research Agreement With Abbott Labs 17
Licensing Agreements 18
Vaccinex Enters into Licensing Agreement with biOasis Technologies 18
Astellas Research Institute of America Enters into License Agreement with biOasis Technologies 19
biOasis Enters Into Licensing Agreement With Medimmune For Transcend Brain Delivery Platform 20
Equity Offering 21
Bioasis Raises USD0.7 Million in Private Placement of Shares 21
Bioasis Technologies Raises USD0.5 Million in Second Tranche of Private Placement of Units 22
biOasis Tech Raises USD3 Million in Private Placement of Units 24
Bioasis Tech Raises Funds through Private Placement of Units 25
biOasis Raises USD1.5 Million in Private Placement of Units 26
biOasis Technologies Completes Private Placement Of Units For US$2.5 Million 27
Bioasis Technologies Inc – Key Competitors 28
Bioasis Technologies Inc – Key Employees 29
Bioasis Technologies Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Jul 30, 2018: Bioasis Technologies announces financial results for three months ended May 31, 2018 31
Jun 26, 2018: Bioasis Technologies announces financial results for fiscal 2018 32
Jan 29, 2018: Bioasis Technologies announces financial results for three months ended November 30, 2017 33
Corporate Communications 34
Jul 27, 2018: Bioasis welcomes John E. Curran & David M. Wurzer to the company’s board of directors 34
May 14, 2018: Bioasis announces intention to pursue NASDAQ listing 35
Mar 26, 2018: Bioasis Technologies Appoints Caroline Hill As senior vice president, Research & Development Operations 36
Mar 21, 2018: Bioasis Appoints Deborah Rathjen as Chair of the Board of Directors 37
Dec 04, 2017: Bioasis Implements Transition Plan for Its Board of Directors 38
Oct 02, 2017: biOasis Appoints Christopher P. Lowe, M.B.A. as Chief Financial Officer and Board Advisor 39
Sep 18, 2017: biOasis Announces Rob Hutchison, Founder, to Retire as Chairman & Board Member 40
Sep 07, 2017: biOasis Announces Formation of Scientific Advisory Board to Advance the Science for the Company’s Blood-Brain Barrier Drug Delivery Platform 42
Aug 28, 2017: biOasis Announces Nominees to the Board of Directors, Chairman Transition and Details of its Annual General Meeting of Shareholders 44
Aug 21, 2017: biOasis Appoints Doug Williams, MBA, Executive Vice President, Chief Business Officer 46
Apr 24, 2017: biOasis Appoints Mark Day, Ph.D., as Chief Executive Officer and Director 47
Other Significant Developments 48
Jun 14, 2017: biOasis CEO Dr. Mark Day Releases Details of Corporate Plans in Message to Shareholders 48
Jan 22, 2017: biOasis Provides AGM Update — Expanding The biOasis Deal Flow Pipeline 50
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52

List of Tables
Bioasis Technologies Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Bioasis Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Bioasis Technologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Bioasis Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Bioasis Technologies Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Bioasis Technologies Inc, Medical Devices Deals, 2012 to YTD 2018 10
Bioasis Technologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Bioasis Technologies and BioAgilytix Enter into Co-Development Agreement 12
Bioasis Technologies Enters into Agreement with Wuxi Biologics 13
biOasis Technologies Enters into Research Agreement with Brigham and Women's Hospital 14
Bioasis Enters into Collaborative Research Agreement with Brain Canada 15
biOasis Technologies Enters Into Research Agreement With UCB 16
biOasis Technologies Enters Into Research Agreement With Abbott Labs 17
Vaccinex Enters into Licensing Agreement with biOasis Technologies 18
Astellas Research Institute of America Enters into License Agreement with biOasis Technologies 19
biOasis Enters Into Licensing Agreement With Medimmune For Transcend Brain Delivery Platform 20
Bioasis Raises USD0.7 Million in Private Placement of Shares 21
Bioasis Technologies Raises USD0.5 Million in Second Tranche of Private Placement of Units 22
biOasis Tech Raises USD3 Million in Private Placement of Units 24
Bioasis Tech Raises Funds through Private Placement of Units 25
biOasis Raises USD1.5 Million in Private Placement of Units 26
biOasis Technologies Completes Private Placement Of Units For US$2.5 Million 27
Bioasis Technologies Inc, Key Competitors 28
Bioasis Technologies Inc, Key Employees 29
Bioasis Technologies Inc, Other Locations 30
Bioasis Technologies Inc, Subsidiaries 30

List of Figures
Bioasis Technologies Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Bioasis Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Bioasis Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Bioasis Technologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Bioasis Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Bioasis Technologies Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Bioasis Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Bioasis Technologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Bioasis Technologies Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Bioasis Technologies Inc (BTI):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • ALLETE Inc (ALE):企業の財務・戦略的SWOT分析
    ALLETE Inc (ALE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Bharat Heavy Electricals Limited (BHEL):企業の戦略・SWOT・財務情報
    Bharat Heavy Electricals Limited (BHEL) - Strategy, SWOT and Corporate Finance Report Summary Bharat Heavy Electricals Limited (BHEL) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Melinta Therapeutics Inc (MLNT):企業の財務・戦略的SWOT分析
    Melinta Therapeutics Inc (MLNT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Incitec Pivot Ltd (IPL):企業の財務・戦略的SWOT分析
    Incitec Pivot Ltd (IPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • GEN energija, d.o.o.:発電所・企業SWOT分析
    GEN energija, d.o.o. - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employee …
  • 3D Medicines Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary 3D Medicines Corp (3D Medicines) is a precision medicine company. The company provides cancer precision medical treatment. It offers cancer diagnosis and treatment through the integration of biological characteristics, clinical diagnosis and treatment, and drug research and development data …
  • Orbis S.A.:企業の戦略・SWOT・財務情報
    Orbis S.A. - Strategy, SWOT and Corporate Finance Report Summary Orbis S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Tata Power Solar Systems Ltd:企業の戦略的SWOT分析
    Tata Power Solar Systems Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Laing O’Rourke Australia Pty Ltd:企業の戦略的SWOT分析
    Laing O'Rourke Australia Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Dermira Inc (DERM):製薬・医療:M&Aディール及び事業提携情報
    Summary Dermira Inc (Dermira) is a biopharmaceutical company that identifies, develops and commercializes therapeutic solutions for the treatment of dermatologic diseases, such as hyperhidrosis, acne vulgaris and atopic dermatitis. The company’s product includes QBREXZA (glycopyrronium) cloth, an an …
  • Colas SA (RE):企業の財務・戦略的SWOT分析
    Colas SA (RE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Lensar Inc-医療機器分野:企業M&A・提携分析
    Summary Lensar Inc (Lensar), a subsidiary of Alphaeon Corp is a medical device company that designs, develops and manufactures laser and advanced 3D imaging technology and devices for refractive cataract surgery. The company provides surgeon with superior femtosecond laser technology. It offers vari …
  • SeaBird Exploration PLC (SBX)-石油・ガス分野:企業M&A・提携分析
    Summary SeaBird Exploration Ltd (SeaBird) is an oil and gas company that provides marine 2D and 3D seismic data services. The company’s services include 2D seismic acquisition, 3D and 3D shallow water acquisition and source vessel. Its source vessels offers services such as conventional undershoots, …
  • Siemens AG (SIE):企業の財務・戦略的SWOT分析
    Siemens AG (SIE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • China Everbright Bank Co., Ltd.:戦略・SWOT・企業財務分析
    China Everbright Bank Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary China Everbright Bank Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Sembcorp Industries Ltd (U96):石油・ガス:M&Aディール及び事業提携情報
    Summary Sembcorp Industries Ltd (Sembcorp) is a diversified energy, water and marine company. It provides solutions across the energy and utilities value chain, with a focus on gas and power, renewables and environment, and merchant and retail sectors. The company carries out production and supply o …
  • OmniGuide Inc:医療機器:M&Aディール及び事業提携情報
    Summary OmniGuide Inc (OmniGuide) is a medical device company that offers microsurgery, laparoscopy, and robotic assisted surgery products. The company’s products comprise GYN systems, ENT systems, OTO systems, line of sight systems, robotic surgical products and others. It also offers gynecology su …
  • Keepmoat Ltd:企業の戦略的SWOT分析
    Keepmoat Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Chiesi Farmaceutici SpA:企業の戦略的SWOT分析
    Chiesi Farmaceutici SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Sumitomo Dainippon Pharma Co., Ltd.:企業の戦略・SWOT・財務分析
    Sumitomo Dainippon Pharma Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Sumitomo Dainippon Pharma Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆